SAGE Therapeutics Inc  

(Public, NASDAQ:SAGE)   Watch this stock  
Find more results for SAGE
162.32
+4.29 (2.71%)
Dec 15 - Close
NASDAQ real-time data - Disclaimer
Currency in USD
Range 155.72 - 163.98
52 week 44.55 - 173.36
Open 159.00
Vol / Avg. 1.18M/1.42M
Mkt cap 6.84B
P/E     -
Div/yield     -
EPS -6.87
Shares 41.05M
Beta 3.03
Inst. own 102%
Dec 14, 2017
SAGE Therapeutics Inc at BMO Capital Markets Prescriptions for Success Healthcare Conference
Dec 7, 2017
Sage Therapeutics, Inc. - Special Call - Webcast
Nov 9, 2017
Sage Therapeutics, Inc. - Special Call - Webcast
Nov 2, 2017
Q3 2017 SAGE Therapeutics Inc Earnings Call - Webcast
Sep 27, 2017
SAGE Therapeutics Inc at Leerink Partners Roundtable Series: Rare Disease & Immuno-Oncology
More events from DailyFinance »    

Key stats and ratios

Q3 (Sep '17) 2016
Net profit margin - -
Operating margin - -
EBITD margin - -
Return on average assets -108.61% -53.57%
Return on average equity -128.46% -58.64%
Employees 135 -
CDP Score - -

Address

215 1st St
CAMBRIDGE, MA 02142-1213
United States - Map
+1-617-2998380 (Phone)
+1-617-2998379 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money

Description

SAGE Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is engaged in developing and commercializing medicines to treat central nervous system (CNS) disorders. The Company's lead product candidate, SAGE-547 is an intravenous formulation of allopregnanolone, a neurosteroid that acts as a synaptic and extrasynaptic modulator of the Gamma-Amino Butyric Acid-A (GABAA) receptor. The Company's next-generation product candidates, SAGE-217 and SAGE-689, also target the GABAA receptor system. The Company is focused on developing drugs based on selective allosteric modulation of CNS synaptic and extrasynaptic receptors. The Company's chemistry platform is focused on the chemical scaffolds of endogenous or chemically modified synthetic neuroactive steroid compounds that are allosteric modulators of GABAA or N-Methyl-D-aspartic acid or N-Methyl-D-aspartate (NMDA) receptors.

Officers and directors

Kevin P. Starr Independent Chairman of the Board
Age: 54
Bio & Compensation  - Reuters
Jeffrey M. Jonas M.D. President, Chief Executive Officer, Director
Age: 64
Bio & Compensation  - Reuters
Kimi E. Iguchi Chief Financial Officer, Treasurer
Age: 53
Bio & Compensation  - Reuters
Anne Marie Cook Senior Vice President, General Counsel
Age: 54
Bio & Compensation  - Reuters
Amy Schacterle Ph.D. Senior Vice President - Regulatory Affairs and Quality Assurance
Bio & Compensation  - Reuters
Christopher Silber Senior Vice President - Clinical Development
Bio & Compensation  - Reuters
Albert J. Robichaud Ph.D. Chief Scientific Officer
Age: 54
Bio & Compensation  - Reuters
Frank Sanders Vice President of Sales and Marketing
Bio & Compensation  - Reuters
Paul Hodgkins Vice President - Health Economics and Outcomes Research and Value Demonstration
Bio & Compensation  - Reuters
Thomas D. Anderson Chief Commercial Strategy Officer
Age: 60
Bio & Compensation  - Reuters